तुलना करने के लिए मीट्रिक्स | FATE | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधFATEपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −2.0x | −1.3x | −0.2x | |
PEG अनुपात | −0.07 | −0.01 | 0.00 | |
क़ीमत/बुक | 1.6x | 0.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 38.6x | 4.1x | 2.8x | |
अपसाइड (विश्लेषक लक्ष्य) | 174.9% | 656.3% | 62.7% | |
उचित मूल्य अपसाइड | अनलॉक करें | 25.8% | 8.0% | अनलॉक करें |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.